{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=30",
    "query": {
      "intervention": "Formulation #2",
      "page": 30
    },
    "page_size": 10
  },
  "pagination": {
    "page": 30,
    "page_size": 10,
    "total_count": 1743,
    "total_pages": 175,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=31&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=29&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T11:41:11.549Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02322879",
      "title": "Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acetaminophen Toxicity"
      ],
      "interventions": [
        {
          "name": "First Treatment Period",
          "type": "DRUG"
        },
        {
          "name": "Washout",
          "type": "OTHER"
        },
        {
          "name": "Second Treatment Period",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "20 Years to 40 Years"
      },
      "enrollment_count": 21,
      "start_date": "2013-05",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2017-09-01",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02322879"
    },
    {
      "nct_id": "NCT05092373",
      "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Fallopian Tube Carcinoma",
        "Advanced Hepatocellular Carcinoma",
        "Advanced Malignant Abdominal Neoplasm",
        "Advanced Malignant Female Reproductive System Neoplasm",
        "Advanced Malignant Thoracic Neoplasm",
        "Advanced Ovarian Carcinoma",
        "Advanced Primary Peritoneal Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Anatomic Stage IIIB Breast Cancer AJCC v8",
        "Anatomic Stage IIIC Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Malignant Abdominal Neoplasm",
        "Malignant Solid Neoplasm",
        "Metastatic Breast Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Fallopian Tube Carcinoma",
        "Metastatic Hepatocellular Carcinoma",
        "Metastatic Malignant Abdominal Neoplasm",
        "Metastatic Malignant Female Reproductive System Neoplasm",
        "Metastatic Malignant Thoracic Neoplasm",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Primary Peritoneal Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Prognostic Stage III Breast Cancer AJCC v8",
        "Prognostic Stage IIIA Breast Cancer AJCC v8",
        "Prognostic Stage IIIB Breast Cancer AJCC v8",
        "Prognostic Stage IIIC Breast Cancer AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Stage III Fallopian Tube Cancer AJCC v8",
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Primary Peritoneal Cancer AJCC v8",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage IIIA Fallopian Tube Cancer AJCC v8",
        "Stage IIIA Hepatocellular Carcinoma AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Primary Peritoneal Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIA1 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Fallopian Tube Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Fallopian Tube Cancer AJCC v8",
        "Stage IIIB Hepatocellular Carcinoma AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Primary Peritoneal Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Fallopian Tube Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Primary Peritoneal Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Hepatocellular Carcinoma AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Hepatocellular Carcinoma AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Tumor Treating Fields Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2022-04-29",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05092373"
    },
    {
      "nct_id": "NCT00853554",
      "title": "Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Hydromorphone Hydrochloride tablet 8 mg",
          "type": "DRUG"
        },
        {
          "name": "Dilaudid® tablet 8 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2002-12",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853554"
    },
    {
      "nct_id": "NCT04145518",
      "title": "Mechanistic Characterization of Uterine Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dysmenorrhea (Disorder)",
        "Dysmenorrhea Primary",
        "Dysmenorrhea Secondary",
        "Endometrial Diseases",
        "Leiomyoma",
        "Fibroid Uterus"
      ],
      "interventions": [
        {
          "name": "Naproxen Sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 183,
      "start_date": "2019-10-25",
      "completion_date": "2025-07-23",
      "has_results": true,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 1,
      "location_summary": "Evanston, Illinois",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04145518"
    },
    {
      "nct_id": "NCT00865462",
      "title": "A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Abrika Bupropion 150 mg XL Tablet, single dose",
          "type": "DRUG"
        },
        {
          "name": "Wellbutrin XL® 150 mg Tablet, single dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-07",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2010-08-16",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 1,
      "location_summary": "Fort Myers, Florida",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865462"
    },
    {
      "nct_id": "NCT02995161",
      "title": "Sun Protection Factor Assay (344/2016)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sunscreening Agents"
      ],
      "interventions": [
        {
          "name": "BAY987521",
          "type": "DRUG"
        },
        {
          "name": "SPF control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-12-30",
      "completion_date": "2017-01-04",
      "has_results": false,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 1,
      "location_summary": "Union, New Jersey",
      "locations": [
        {
          "city": "Union",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02995161"
    },
    {
      "nct_id": "NCT02742103",
      "title": "A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myocardial Infarction",
        "Moderate Renal Impairment"
      ],
      "interventions": [
        {
          "name": "CSL_112",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2016-08",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-06-11",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02742103"
    },
    {
      "nct_id": "NCT02073227",
      "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Canagliflozin, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR, 500 mg",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2014-02",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-09-09",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02073227"
    },
    {
      "nct_id": "NCT02608320",
      "title": "A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Duragesic (Fentanyl Transdermal System [TDS] Small Patches)",
          "type": "DRUG"
        },
        {
          "name": "New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)",
          "type": "DRUG"
        },
        {
          "name": "Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)",
          "type": "DRUG"
        },
        {
          "name": "Duragesic (Fentanyl TDS Large Patches)",
          "type": "DRUG"
        },
        {
          "name": "New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)",
          "type": "DRUG"
        },
        {
          "name": "Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2015-11-17",
      "completion_date": "2016-04-13",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02608320"
    },
    {
      "nct_id": "NCT04404569",
      "title": "Continued Treatment for Participants Enrolled in Studies of BXQ-350",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "BXQ-350",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 5,
      "start_date": "2020-06-08",
      "completion_date": "2024-09-23",
      "has_results": false,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-11-04T11:41:11.549Z",
      "location_count": 3,
      "location_summary": "Lexington, Kentucky • Cincinnati, Ohio • Columbus, Ohio",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04404569"
    }
  ]
}